Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 7/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | TSLP | Q969D9 | 2/20 | 0.54 |
| ▸ | F12 | P00748 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20375015 | 0.93 | EPHA2 (0.63) | EPHA2ACE2KLKB1ACETSLP | |
| SCHEMBL18375845 | 0.91 | EPHA2 (0.58) | EPHA2ACE2KLKB1ACETSLP | |
| SCHEMBL18375815 | 0.91 | EPHA2 (0.58) | EPHA2ACE2KLKB1ACETSLP | |
| SCHEMBL20375008 | 0.91 | EPHA2 (0.58) | EPHA2ACE2KLKB1ACETSLP | |
| SCHEMBL18375843 | 0.90 | EPHA2 (0.55) | EPHA2ACE2KLKB1ACEF12 | |
| SCHEMBL20374825 | 0.89 | EPHA2 (0.56) | EPHA2ACE2KLKB1ACETSLP | |
| SCHEMBL18375846 | 0.88 | EPHA2 (0.53) | EPHA2ACE2KLKB1ACETSLP | |
| SCHEMBL18375806 | 0.87 | KLKB1 (0.53) | EPHA2ACE2KLKB1ACEF12 | |
| SCHEMBL20374834 | 0.86 | KLKB1 (0.53) | EPHA2ACE2KLKB1ACEF12 | |
| SCHEMBL20374824 | 0.85 | EPHA2 (0.52) | EPHA2ACE2KLKB1ACEF12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193409-A1 | PEPTIDYL TPOR ANTAGONISTS AND USES THEREOF | POLYMERS CRC LIMITED (AU) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193409-A1 | PEPTIDYL TPOR ANTAGONISTS AND USES THEREOF | SCTR, QRFPR, NPY1R | EPHA2 1614/4885ACE2 2520/4885KLKB1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.